Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | PLA2G4B | P0C869 | 5/20 | 0.51 |
| ▸ | RARB | P10826 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 3/20 | 0.49 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7777016 | 1.00 | NR5A1 (0.54) | NR5A1TP53TSHRPLA2G4BRARB | |
| SCHEMBL9162002 | 1.00 | NR5A1 (0.54) | NR5A1TP53TSHRPLA2G4BRARB | |
| SCHEMBL9702597 | 1.00 | NR5A1 (0.54) | NR5A1TP53TSHRPLA2G4BRARB | |
| SCHEMBL11848774 | 1.00 | NR5A1 (0.54) | NR5A1TP53TSHRPLA2G4BRARB | |
| SCHEMBL1020538 | 1.00 | NR5A1 (0.54) | NR5A1TP53TSHRPLA2G4BRARB | |
| SCHEMBL414168 | 0.95 | CYP1A2 (0.50) | NR5A1TP53TSHRRAB9ALMNA | |
| SCHEMBL6888218 | 0.93 | NR5A1 (0.47) | NR5A1TP53TSHRPLA2G4BRARB | |
| SCHEMBL7602206 | 0.91 | TSHR (0.50) | NR5A1TP53TSHRPLA2G4BGAA | |
| SCHEMBL10703892 | 0.91 | TSHR (0.50) | NR5A1TP53TSHRPLA2G4BGAA | |
| SCHEMBL7001372 | 0.90 | CYP1A2 (0.46) | NR5A1TP53TSHRRAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108912599-B | Filter film obtained by compounding nitrile rubber and phenolic resin | 长春峰泰汽车胶业有限公司 | 2020-12-25 | — | — | CN | claimed |
| CN-108912599-A | The filter film that a kind of nitrile rubber and phenolic resin compound | 长春峰泰汽车胶业有限公司 | 2018-11-30 | — | — | CN | claimed |
| CN-109021266-B | Preparation method of filter film | 长春峰泰汽车胶业有限公司 | 2021-02-12 | — | — | CN | disclosed |
| CN-108912599-B | Filter film obtained by compounding nitrile rubber and phenolic resin | 长春峰泰汽车胶业有限公司 | 2020-12-25 | — | — | CN | disclosed |
| CN-109021266-A | A kind of preparation method of filter film | 长春峰泰汽车胶业有限公司 | 2018-12-18 | — | — | CN | disclosed |
| CN-108912599-A | The filter film that a kind of nitrile rubber and phenolic resin compound | 长春峰泰汽车胶业有限公司 | 2018-11-30 | — | — | CN | disclosed |
| US-10093624-B2 | NAMPT and ROCK inhibitors | ABBVIE INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20160031880-A1 | Nampt and Rock Inhibitors | ABBVIE INC. (US) | 2016-02-04 | — | — | US | disclosed |
| EP-2640698-A1 | NAMPT AND ROCK INHIBITORS | AbbVie Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| CN-103313968-A | Nampt and rock inhibitors | ABBVIE LAB | 2013-09-18 | — | — | CN | disclosed |
| EP-1458697-B1 | BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS | GALDERMA RES & DEV (FR) | 2006-09-06 | — | — | EP | disclosed |
| CN-1639138-A | Biphenylmethyl-thiazolidinediones and analogues and their use as PPAR-gamma activators | GALDERMA RES & DEV (FR) | 2005-07-13 | — | — | CN | disclosed |
| US-20050137238-A1 | Biaromatic ligand activators of PPARgamma receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. | 2005-06-23 | — | — | US | disclosed |
| US-6908939-B2 | Biaromatic ligand activators of PPARγ receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2005-06-21 | — | — | US | disclosed |
| EP-1458697-A1 | BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS | Galderma Research & Development, S.N.C. (FR) | 2004-09-22 | — | — | EP | disclosed |
| US-20030134885-A1 | Biaromatic ligand activators of PPARgamma receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-07-17 | — | — | US | disclosed |
| WO-2003055867-A1 | BIPHENYLMETHYL-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE AS PPAR-GAMMA ACTIVATORS | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2003-07-10 | — | — | WO | disclosed |
| US-4053298-A | HERBICIDAL COMPOSITIONS CONTAINING 1-THIADIAZOLYL-6-CARBAMOYLOXYTETRAHYDROPYRIMIDINONES AND METHODS THEREFOR | VELSICOL CHEMICAL CORPORATION (US) | 1977-10-11 | — | — | US | disclosed |
| US-3951976-A | 1-Thiadiazoly-6-carbamoyloxytetrahydropyrimidinones | VELSICOL CHEMICAL CORPORATION (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10093624-B2 | NAMPT and ROCK inhibitors | NAMPT, NNMT, NADK | NR5A1 3599/4885TP53 4549/4885TSHR 3368/4885 |
| US-20050137238-A1 | Biaromatic ligand activators of PPARgamma receptors | PPARG, PPARA, PPARD | NR5A1 161/4885TP53 384/4885TSHR 184/4885 |
| US-20160031880-A1 | Nampt and Rock Inhibitors | NAMPT, NNMT, NME2 | NR5A1 1843/4885TP53 4592/4885TSHR 2661/4885 |
| US-20030134885-A1 | Biaromatic ligand activators of PPARgamma receptors | PPARG, PPARA, PPARD | NR5A1 146/4885TP53 393/4885TSHR 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.